Case Report
Year 2021,
Volume: 3 Issue: Supplement 1, 92 - 93, 07.03.2021
Abstract
References
- Reference1. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317-2337. doi:10.1002/jbmr.483
- Reference2. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391-403. doi:10.1056/NEJMcp0803050
- Reference3. Russell CF, Edis AJ. Surgery for primary hyperparathyroidism: experience with 500 consecutive cases and evaluation of the role of surgery in the asymptomatic patient. Br J Surg. 1982;69(5):244-247. doi:10.1002/bjs.1800690503
- Reference4. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996;276(8):631-636.
- Reference5. Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med. 2019;380(18):1738-1747. doi:10.1056/NEJMcp1800213
- Reference6. Gafni RI, Langman CB, Guthrie LC, et al. Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity. J Bone Miner Res. 2018;33(10):1741-1747. doi:10.1002/jbmr.3480
- Reference7. Goujard C, Salenave S, Briot K, Chanson P, Grimon G, Kamenický P. Treating hypoparathyroidism with recombinant human parathyroid hormone (1-34): long-term safety concerns. Lancet. 2020;395(10232):1304. doi:10.1016/S0140-6736(20)30538-9
Year 2021,
Volume: 3 Issue: Supplement 1, 92 - 93, 07.03.2021
Abstract
Postsurgical chronic hypoparathyroidism is most commonly seen in adults. Synthetic recombinant human parathyroid hormone (rhPTH) 1-34 can be used to stabilize serum calcium levels in patients with resistant hypocalcemia in rare conditions.
Here we report a 52-year-old woman with postsurgical uncontrolled hypocalcemia despite the usual therapy. Once-daily treatment with PTH 1-34 maintained serum calcium within the normal range and reduced the dose of previous medical therapies.
Keywords
References
- Reference1. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317-2337. doi:10.1002/jbmr.483
- Reference2. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391-403. doi:10.1056/NEJMcp0803050
- Reference3. Russell CF, Edis AJ. Surgery for primary hyperparathyroidism: experience with 500 consecutive cases and evaluation of the role of surgery in the asymptomatic patient. Br J Surg. 1982;69(5):244-247. doi:10.1002/bjs.1800690503
- Reference4. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996;276(8):631-636.
- Reference5. Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med. 2019;380(18):1738-1747. doi:10.1056/NEJMcp1800213
- Reference6. Gafni RI, Langman CB, Guthrie LC, et al. Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity. J Bone Miner Res. 2018;33(10):1741-1747. doi:10.1002/jbmr.3480
- Reference7. Goujard C, Salenave S, Briot K, Chanson P, Grimon G, Kamenický P. Treating hypoparathyroidism with recombinant human parathyroid hormone (1-34): long-term safety concerns. Lancet. 2020;395(10232):1304. doi:10.1016/S0140-6736(20)30538-9
There are 7 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Case Report |
| Authors | |
| Submission Date | February 18, 2021 |
| Acceptance Date | March 6, 2021 |
| Publication Date | March 7, 2021 |
| Published in Issue | Year 2021 Volume: 3 Issue: Supplement 1 |
e-ISSN: 2687-4245
Turkish Journal of Internal Medicine, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2026 -TJIM.org